^
Association details:
| Biomarker: | MTOR S2215Y |
|---|---|
| Cancer: | Melanoma |
| Drug: | LY294002 (PI3K inhibitor, AKT inhibitor, FAK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors
Excerpt:
Consistent with the results of Western blotting, proliferations of HEK293T cells stably expressing H1968Y, P2213S, and S2215Y mTOR mutants were more significantly inhibited by AZD5363 and LY294002 than BYL719 and Temsirolimus (Fig. 3C–J and Supplementary Table S6).
DOI:
10.1158/1078-0432.CCR-15-1110
